# New brainstem targets for counteracting opioid induced apnea

> **NIH NIH R21** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $156,000

## Abstract

ABSTRACT
While prescription opioids are exceptional analgesics, they have significant side effects, especially opioid-
induced persistent apnea (OIPA). A significant public health problem follows from these side effects, as
overdoses caused almost 50,000 deaths in 2019, along with non-fatal overdoses that result in costly and often
extended hospitalization. The “opioid epidemic” accelerated further during the COVID-19 pandemic, with a
38% increase in deaths due to synthetic opioid overdose (primarily fentanyl) compared to 2019. We propose a
logical path to identifying molecules that can block or reverse OIPA that may supplement current treatments,
e.g., higher efficacy and safety, longer half-life, possibly preserving opioid-induced analgesia. Opioids depress
breathing by actions on two brainstem neural circuits underlying breathing movements, the preBötzinger
Complex (preBötC) and the Parabrachial Nuclei (PB), both of which contains neurons expressing µ-opioid
receptors (µORs). µORs are inhibitory G-protein coupled receptors (GPCRs) that depress neuronal excitability.
Activation of excitatory GPCRs in preBötC and PB can counteract opioid effects on breathing. We propose to
sequence the RNA in preBötC and PB neurons that express µORs to determine expression of excitatory
GPCRs. Previous studies in awake mice aimed to determine whether preBötC or PB mediates depression of
breathing during opioid overdose; however, opioids evoke only a modest decrease in breathing in awake mice,
nowhere near an apnea observed in humans during acute opioid intoxication. We therefore propose to
determine whether preBötC and/or PB are primarily responsible for OIPA in mice using a methodology in which
we consistently evoke a complete apnea following opioid administration. We will select potential target
excitatory GPCR receptors, that are coexpressed with µORs in the structure(s) that we find to be primarily
responsible for OIPA (preBötC and/or PB). We will then determine the efficacy of the agonists of these GPCRs
in counteracting OIPA in anesthetized mice. Success of this exploratory project will generate data for
subsequent preclinical and translational investigation of agonists of these receptors as potential therapeutics
for reversing OIPA. Prescription opioids are extremely effective painkillers, but overdose can result in death
because they also stop breathing. More that 50,000 Americans die each year from opioid overdose. We
propose to identify receptors, whose activation can reverse opioids’ effects on breathing.

## Key facts

- **NIH application ID:** 10661014
- **Project number:** 5R21DA054383-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** JACK L FELDMAN
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $156,000
- **Award type:** 5
- **Project period:** 2022-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10661014

## Citation

> US National Institutes of Health, RePORTER application 10661014, New brainstem targets for counteracting opioid induced apnea (5R21DA054383-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10661014. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*